Literature DB >> 24487593

Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma.

Motoko Sasaki1, Takashi Matsubara, Yuko Kakuda, Yasunori Sato, Yasuni Nakanuma.   

Abstract

Intrahepatic cholangiocarcinoma arising in chronic advanced liver disease sometimes contains a component of cholangiolocellular carcinoma. Bile duct adenoma, a benign tumor/tumorous lesion and ductular reaction, is also composed of bile ductular cells, and the differential diagnosis is sometimes difficult. We have previously reported that cholangiolocellular carcinoma showed overexpression of a polycomb group protein EZH2, which participates in bypass/escape from cellular senescence during carcinogenesis. In contrast, the ductular reaction showed high expression of senescence-associated p16(INK4a). In this study, we examined whether immunostaining for EZH2 and p16(INK4a) is useful for differential diagnosis among cholangiolocellular carcinoma, bile duct adenoma, and ductular reactions. Subjects included 33 patients with intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma with components of cholangiolocellular carcinoma and 16 patients with bile duct adenoma. The expressions of EZH2 and p16(INK4a) were examined immunohistochemically. The expression of EZH2 was seen in all cases of cholangiolocellular carcinomas, but it was not observed in bile duct adenomas and ductular reactions, which were seen around carcinomas in 80% of cases. The extensive expression of p16(INK4a) was seen only in 4 cases of cholangiolocellular carcinomas (12%). In contrast, the expression of p16(INK4a) was seen in 13 cases (81%) of bile duct adenomas and in all cases of ductular reactions. The borderline between the component of cholangiolocellular carcinoma and the surrounding ductular reaction was clearly highlighted by the reverse expression pattern of EZH2 and p16(INK4a) in 69% of cases. In conclusion, immunostaining for EZH2 and p16(INK4a) may be useful for differential diagnosis among cholangiolocellular carcinomas, bile duct adenomas, and ductular reactions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24487593     DOI: 10.1097/PAS.0000000000000125

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

Review 1.  Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis.

Authors:  Gábor Lendvai; Tímea Szekerczés; Idikó Illyés; Réka Dóra; Endre Kontsek; Alíz Gógl; András Kiss; Klára Werling; Ilona Kovalszky; Zsuzsa Schaff; Katalin Borka
Journal:  Pathol Oncol Res       Date:  2018-11-17       Impact factor: 3.201

2.  Clinical features and diagnostic imaging of cholangiolocellular carcinoma compared with other primary liver cancers: a surgical perspective.

Authors:  Hiroyuki Takamura; Ryousuke Gabata; Yoshinao Obatake; Shinichi Nakanuma; Hironori Hayashi; Kazuto Kozaka; Motoko Sasaki; Mitsuyoshi Okazaki; Takahisa Yamaguchi; Hiroyuki Shimbashi; Shiro Terai; Koichi Okamoto; Isamu Makino; Jun Kinoshita; Keishi Nakamura; Tomoharu Miyashita; Hidehiro Tajima; Itasu Ninomiya; Sachio Fushida; Azusa Kitao; Masaaki Kitahara; Kuniaki Arai; Taro Yamashita; Tatsuya Yamashita; Hiroko Ikeda; Yasunori Satoh; Kenichi Harada; Syuichi Kaneko; Toshihumi Gabata; Tateo Kosaka; Tetsuo Ohta
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

3.  High BLM Expression Predicts Poor Clinical Outcome and Contributes to Malignant Progression in Human Cholangiocarcinoma.

Authors:  Xiaolong Du; Chen Zhang; Chuanzheng Yin; Wenjie Wang; Xueke Yan; Dawei Xie; Xichuan Zheng; Qichang Zheng; Min Li; Zifang Song
Journal:  Front Oncol       Date:  2021-03-22       Impact factor: 6.244

4.  Cancer-Associated Fibroblast-Derived IL-6 Determines Unfavorable Prognosis in Cholangiocarcinoma by Affecting Autophagy-Associated Chemoresponse.

Authors:  Suyanee Thongchot; Chiara Vidoni; Alessandra Ferraresi; Watcharin Loilome; Narong Khuntikeo; Sakkarn Sangkhamanon; Attapol Titapun; Ciro Isidoro; Nisana Namwat
Journal:  Cancers (Basel)       Date:  2021-04-28       Impact factor: 6.639

Review 5.  Benign biliary neoplasms and biliary tumor precursors.

Authors:  Samantha Sarcognato; Diana Sacchi; Matteo Fassan; Luca Fabris; Massimiliano Cadamuro; Giacomo Zanus; Ivana Cataldo; Claudia Covelli; Paola Capelli; Alberto Furlanetto; Maria Guido
Journal:  Pathologica       Date:  2021-06

6.  Identification of novel biomarker candidates for the immunohistochemical diagnosis of cholangiocellular carcinoma.

Authors:  Juliet Padden; Dominik A Megger; Thilo Bracht; Henning Reis; Maike Ahrens; Michael Kohl; Martin Eisenacher; Jörg F Schlaak; Ali E Canbay; Frank Weber; Andreas-Claudius Hoffmann; Katja Kuhlmann; Helmut E Meyer; Hideo A Baba; Barbara Sitek
Journal:  Mol Cell Proteomics       Date:  2014-07-17       Impact factor: 5.911

7.  DNA Methylation Markers Improve the Sensitivity of Endoscopic Retrograde Cholangiopancreatography-Based Brushing Cytology in Extrahepatic Cholangiocarcinoma.

Authors:  Varayu Prachayakul; Jiraporn Kanchanapermpoon; Chanitra Thuwajit; Thiraphon Boonyaarunnate; Ananya Pongpaibul; Pornpimol Chobson; Peti Thuwajit
Journal:  Technol Cancer Res Treat       Date:  2017-12

Review 8.  Cholangiocarcinoma.

Authors:  Samantha Sarcognato; Diana Sacchi; Matteo Fassan; Luca Fabris; Massimiliano Cadamuro; Giacomo Zanus; Ivana Cataldo; Paola Capelli; Francesca Baciorri; Matilde Cacciatore; Maria Guido
Journal:  Pathologica       Date:  2021-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.